Cargando…
Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783447/ https://www.ncbi.nlm.nih.gov/pubmed/29379898 http://dx.doi.org/10.1210/js.2017-00354 |
_version_ | 1783295279494070272 |
---|---|
author | Bustos, Mario Berger, Hara Hannoush, Zeina Carolina Ayala, Alejandro Freire, Rochelle Kargi, Atil Yilmaz |
author_facet | Bustos, Mario Berger, Hara Hannoush, Zeina Carolina Ayala, Alejandro Freire, Rochelle Kargi, Atil Yilmaz |
author_sort | Bustos, Mario |
collection | PubMed |
description | Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenous immunoglobulin (IVIG). A literature review was conducted to identify prior studies pertaining to LHT. Our patient presented with several weeks of fatigue, cold intolerance, weight loss, confusion, and headache. Laboratory tests were consistent with panhypopituitarism. Brain magnetic resonance imaging revealed an infiltrative enhancing mass in the area of the hypothalamus, and stereotactic biopsy findings showed reactive inflammatory changes. A course of hormone replacement (levothyroxine), methylprednisolone, and IVIG was initiated. The patient’s course was complicated by a fatal tonsillar herniation. Autopsy revealed LHT. The diagnosis and management of autoimmune LHT are challenging. The entity should be considered in the setting of panhypopituitarism with a hypothalamic mass. Differentiating paraneoplastic and nonparaneoplastic hypothalamitis should be established for management and prognosis. Definitive treatment remains unclear; treatment with corticosteroids should be attempted, followed by consideration of other immunosuppressive agents, such as rituximab. If a paraneoplastic syndrome is suspected, management should also be directed toward the primary tumor. |
format | Online Article Text |
id | pubmed-5783447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-57834472018-01-29 Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis Bustos, Mario Berger, Hara Hannoush, Zeina Carolina Ayala, Alejandro Freire, Rochelle Kargi, Atil Yilmaz J Endocr Soc Case Reports Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenous immunoglobulin (IVIG). A literature review was conducted to identify prior studies pertaining to LHT. Our patient presented with several weeks of fatigue, cold intolerance, weight loss, confusion, and headache. Laboratory tests were consistent with panhypopituitarism. Brain magnetic resonance imaging revealed an infiltrative enhancing mass in the area of the hypothalamus, and stereotactic biopsy findings showed reactive inflammatory changes. A course of hormone replacement (levothyroxine), methylprednisolone, and IVIG was initiated. The patient’s course was complicated by a fatal tonsillar herniation. Autopsy revealed LHT. The diagnosis and management of autoimmune LHT are challenging. The entity should be considered in the setting of panhypopituitarism with a hypothalamic mass. Differentiating paraneoplastic and nonparaneoplastic hypothalamitis should be established for management and prognosis. Definitive treatment remains unclear; treatment with corticosteroids should be attempted, followed by consideration of other immunosuppressive agents, such as rituximab. If a paraneoplastic syndrome is suspected, management should also be directed toward the primary tumor. Endocrine Society 2018-01-03 /pmc/articles/PMC5783447/ /pubmed/29379898 http://dx.doi.org/10.1210/js.2017-00354 Text en Copyright © 2018 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Reports Bustos, Mario Berger, Hara Hannoush, Zeina Carolina Ayala, Alejandro Freire, Rochelle Kargi, Atil Yilmaz Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title | Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title_full | Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title_fullStr | Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title_full_unstemmed | Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title_short | Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis |
title_sort | anti–ma-1 and anti–ma-2 antibodies in isolated fatal hypothalamitis |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783447/ https://www.ncbi.nlm.nih.gov/pubmed/29379898 http://dx.doi.org/10.1210/js.2017-00354 |
work_keys_str_mv | AT bustosmario antima1andantima2antibodiesinisolatedfatalhypothalamitis AT bergerhara antima1andantima2antibodiesinisolatedfatalhypothalamitis AT hannoushzeinacarolina antima1andantima2antibodiesinisolatedfatalhypothalamitis AT ayalaalejandro antima1andantima2antibodiesinisolatedfatalhypothalamitis AT freirerochelle antima1andantima2antibodiesinisolatedfatalhypothalamitis AT kargiatilyilmaz antima1andantima2antibodiesinisolatedfatalhypothalamitis |